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p21WAF1 and TGF- mediate parathyroid growth arrest by vita- mone (PTH), which in turn increases bone resorption, a
min D and high calcium. feature of renal osteodystrophy [2]. Under physiological
Background. High dietary phosphorus (P) worsens uremia- conditions, PT cells remain quiescent [1–3]. However,induced parathyroid (PT) hyperplasia through increases in the
they retain their potential to proliferate in response togrowth promoter transforming growth factor-alpha (TGF-).
In contrast, P restriction prevents PT hyperplasia by inducing certain stimuli, such as uremia, low calcium (Ca) intake,
the cell cycle inhibitor p21. Since 1,25(OH)2D3-antiproliferative vitamin D deficiency, and high dietary phosphorus (P)
action in various cell types involve increases in p21, we studied [4, 5]. Although the mechanisms by which these factorswhether induction of p21 by 1,25(OH)2D3 or the vitamin D ana-
control PTH biosynthesis and secretion are well known,log, 19-Nor-1,25(OH)2D2, could counteract the PT hyperplasia
the mechanisms responsible for their effects on PT cellinduced by high dietary P in early uremia.
Methods. Normal (N) and uremic (U; 5/6 nephrectomized) proliferation are poorly understood.
female Sprague-Dawley rats were fed high P (HP), low P (LP) The most efficient way to study the regulation of PTor high Ca (HCa) diets and administered intraperitoneally (IP)
tissue growth, synchronized PT cell cultures, is hinderedeither vehicle or vitamin D metabolites for seven days, as fol-
by the lack of an appropriate PT cell line. Therefore,lows: N-HP; U-HP  vehicle; U-HP  1,25(OH)2D3 (4 ng/
day); U-HP 19-Nor-1,25(OH)2D2 (30 ng/day); U-LP; U-HCa. the experimental approach for analyzing the rates of PT
Serum PTH and PT gland weight assessed secondary hyperpara- cell proliferation and apoptosis is limited to the in vivothyroidism. Immunohistochemical quantitation of two markers
uremic rat model. Studies in our laboratory assessingof mitotic activity, Ki67 and PCNA measured PT hyperplasia.
Immunohistochemical expression of PT p21 and TGF- ad- potential mechanisms mediating the opposing effects of
dressed potential mechanisms regulating PT cell growth. high and low dietary P on PT cell growth demonstrated
Results. 1,25(OH)2D3 and 19-Nor-1,25(OH)2D2 were effec- that high dietary P worsens uremia-induced PT hyperpla-tive in suppressing both PTH secretion and PT hyperplasia
sia by increasing PT expression of the growth promoterinduced by uremia and high dietary P independent of increases
in ionized Ca. Both vitamin D compounds enhanced PT p21 transforming growth factor alpha (TGF-) [6]. In con-
expression and prevented high P-induced increases in PT trast, dietary P restriction induces PT growth arrest by
TGF- content. Induction of PT p21 and reduction of TGF- increasing PT content of the cyclin-dependent kinasecontent also occurred when uremia-induced PT hyperplasia
inhibitor, p21 [6].was suppressed by high dietary Ca.
Conclusions. In early uremia, vitamin D suppression of high These studies addressed potential mechanisms for the
P-induced PT hyperplasia and high dietary Ca arrest of PT growth regulation of PT cell growth by 1,25(OH)2D3 and itsinvolve induction of PT p21 and prevention of increases in analog 19-Nor-1,25(OH)2D2. Several laboratories demon-TGF-.
strated a role for 1,25(OH)2D3 in the control of parathy-
roid cell proliferation in vitro [7], and in vivo in uremia-
induced PT hyperplasia in 5/6 nephrectomized rats [8].The control of parathyroid (PT) hyperplasia is crucial
Based on the reported antiproliferative properties ofin preventing secondary hyperparathyroidism in uremic
1,25-dihydroxyvitamin-D3 in PT cells, we first studied thepatients [1]. The enlargement of the PT glands results
efficacy of vitamin D treatment [1,25(OH)2D3 and itsin enhanced synthesis and secretion of parathyroid hor-
analog 19-Nor-1,25(OH)2D2] to counteract the PT hyper-
plasia induced by high dietary P in early uremia. In cellsKey words: hyperplasia, renal failure, growth factors, parathyroid hy-
perplasia, uremia, dietary calcium, secondary hyperparathyroidism. of the monocyte-macrophage lineage [9] as well as in
other cell types [10–12], vitamin D suppresses cell growthReceived for publication December 18, 2000
through the induction of p21. Therefore, to identify po-and in revised form July 3, 2001
Accepted for publication July 9, 2001 tential mechanisms mediating the inhibition of PT cell
proliferation by vitamin D treatment, we first examined 2001 by the International Society of Nephrology
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the contribution of increased PT-p21 expression. Since an autoanalyzer (COBAS-MIRA Plus, Branchburg, NJ,
USA). Serum total Ca was measured by atomic absorp-TGF- content directly correlates with the degree of PT
hyperplasia induced by high dietary P, we also examined tion spectrophotometry using a Perkin-Elmer 1100B
spectrophotometer (Perkin-Elmer, Norwalk, CT, USA).the effects of vitamin D treatment on PT TGF- expres-
sion. Finally, we compared the effects of vitamin D treat- Intact PTH levels were measured by an immunoradio-
metric assay specific for intact rat PTH (Immunotopics,ment on PT p21 and TGF- content with those induced
by high dietary Ca, a well-known promoter of PT growth San Clemente, CA, USA).
arrest in uremia.
ImmunohistochemistryOur results show that vitamin D treatment may pre-
vent high P-induced PT hyperplasia by inducing p21 and Immunohistochemical staining for Ki-67 related anti-
gen (Ki67), proliferating cell nuclear antigen (PCNA),preventing increases in TGF- expression. The suppres-
sion of uremia-induced PT hyperplasia by high dietary p21, and TGF- was performed on sections of formalin-
fixed, paraffin embedded PT glands following protocolsCa also involves changes in PT p21 and TGF- content
similar to those induced by vitamin D therapy, thus sup- described in previous studies for each specific protein
[6]. For Ki67 immunostaining, a mouse monoclonal an-porting these two molecules as important regulators of
PT cell growth. ti-Ki67 antibody (MIB-5, Cat. No.2093; Immunotech,
Marseille, France) was used as the primary antibody.
Specificity of the primary antibodies was tested by immu-
METHODS
nohistochemical staining of rat PT tissue replacing the
Normal and uremic (5/6 nephrectomized) female primary antibody with mouse IgG1. For TGF- immuno-
Sprague-Dawley rats, 5 to 6 weeks old, weighing 225 to staining, PT tissue was pretreated with 0.05% saponin
250 grams were studied. For 5/6 nephrectomy, several for 30 minutes at room temperature. Tissue was then
branches of the left renal artery were ligated and the right blocked with 10% preimmune goat serum and incubated
kidney excised. Rats underwent one of the following with primary antibody (4 g/mL for Ki67, 1.13 g/mL
experimental conditions: (a) normal rats fed a high P for PCNA, 5 g/mL for p21, and 10 g/mL for TGF-)
diet (0.9% P; 0.6% Ca) (N-HP); (b) uremic rats fed the for 12 hours at room temperature. Twenty-four consecu-
same high P diet (U-HP); (c) uremic rats fed the high P tive sections of tissue were cut for each PT gland. Immu-
diet and treated with 4 ng/day of 1,25(OH)2D3 (U-HP  nohistochemical staining of Ki67, PCNA, p21, and TGF-
1,25D); (d) uremic rats fed the high P diet and treated proteins were quantitated. Ki67 and PCNA-positive nu-
with 30 ng/day of 19-Nor-1,25(OH)2D2 (U-HP 19Nor); clei were counted in ten high-power fields (HPF) and
(e) uremic rats fed a low P diet (0.2% P; 0.5% Ca) expressed as the number of positive-staining nuclei per
(U-LP); and ( f) uremic rats fed a high Ca diet (1.25% area, which included sections of the whole PT glands.
P; 2.0% Ca) (U-HCa). Diets were purchased from Dy- Positive staining for p21 was graded as: (–) negative, ()
ets, Inc. (Bethlehem, PA, USA). Both 1,25(OH)2D3 and 25%, () 25 to 50%, and () 50%. Grades
19-Nor-1,25(OH)2D2 were administered intraperitone-  and  were taken as positive staining. Immuno-
ally (IP) in 100 L of propylene glycol. All other experi- histochemical staining was evaluated independently by
mental groups received 100 L of propylene glycol daily three different individuals who were blinded to the origin
as vehicle. The doses of 1,25-dihydroxyvitamin D3 (4 ng of the samples. Ten different slides were analyzed for
daily) and 19-Nor-1,25-dihydroxyvitamin D2 (30 ng daily) each experimental condition.
were chosen from pilot studies designed to control PT Immunohistochemical staining of Ki67, PCNA, and
hyperplasia while avoiding hypercalcemia. TGF- proteins was quantitated using a Nikon Diaphot-
After a seven-day treatment, rats were sacrificed. TMD microscope coupled to a camera and an image
Blood was drawn for analytical determinations. PT glands analysis system. Images of stained tissue sections were
were surgically removed and weighed on a CAHN-31 acquired using a DAGE-330 color camera and captured
microbalance (Cahn Instruments, Inc., Cerritos, CA, with a Pentium P-166 IBM compatible computer. The
USA). For immunohistochemistry, PT glands were kept digitized images were converted to a gray scale and ana-
in 10% formaldehyde overnight and then transferred to lyzed using Image-Pro plus software (Media Cybernet-
70% ethanol in water before mounting. All experimental ics), according to Mize’s study [13], as described before
protocols were approved by the Animal Study Commit- [6]. To eliminate variation, the microscope light source
tee at Washington University School of Medicine. intensity used during image capture was kept constant
for all sections stained on a given day.
Analytical determinations
StatisticsIonized calcium (ICa) was measured by an ICa-specific
electrode (Model ICA-1; Radiometer, Copenhagen, Den- ANOVA was employed to assess statistical differences
between all experimental groups tested. Multiple com-mark). Plasma P and creatinine were determined using
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Table 1. Serum chemistry
N-HP U-HP U-HP1,25D U-HP19Nor U-LP U-HCa
(N9) (N13) (N13) (N7) (N15) (N11)
Creatinine mg/dL 0.700.09 1.690.07b 1.580.08b 1.530.10b 1.530.06b 1.480.10b
P mg/dL 4.310.20 8.130.36b 8.950.39b 8.500.56b 5.760.33a,b 7.170.20b
ICa mg/dL 4.870.09 4.270.07b 4.390.08b 4.660.10a 4.630.05a 5.140.05a,b
Values represent the mean  SEM; N is the number of rats. Abbreviations are: N, normal; U, uremic; HP, high phosphorus; LP, low phosphorus; 1,25D,
1,25(OH)2D3; 19Nor, 19-Nor-1,25(OH)2D3; HCa, high calcium; ICa, ionized calcium.
a P  0.05 vs. U-HP
b P  0.05 vs. N-HP, from Bonferroni analysis comparing each experimental group
parisons using the stringent Bonferroni test measured
the statistical significance of the differences between ev-
ery possible two-group comparison.
RESULTS
The efficacy of 1,25(OH)2D3 and 19-Nor-1,25(OH)2D2
in preventing high P-induced PT hyperplasia in uremic
rats was determined seven days after the induction of
renal insufficiency by 5/6 nephrectomy. Preliminary stud-
ies defined minimal antiproliferative, non-hypercalcemic
doses of the two vitamin D metabolites employed in the
present protocols. To compare the mechanisms mediat-
ing the control of PT growth by vitamin D and high dietary
calcium, we used a diet containing 2.0% Ca to arrest
uremia-induced PT hyperplasia and 1.2% P to prevent
hypophosphatemia.
Serum chemistry
Table 1 shows serum chemistries in normal and uremic
rats for all the experimental condition tested. Serum cre-
atinine increased similarly in all uremic animals regard-
less of dietary P or Ca intake. Serum P levels increased
in all uremic groups compared to normal controls. In
uremic rats fed the high P diet, treatment with either
1,25(OH)2D3 or 19-Nor-1,25(OH)2D2 did not further in-
crease serum P levels. At the doses tested, there was no
significant difference in serum P between 1,25(OH)2D3
and 19-Nor-1,25(OH)2D2 treated animals. As expected, Fig. 1. Effects of vitamin D treatment and high dietary Ca on serum
serum P was lower in the uremic rats fed a 0.2% P diet parathyroid hormone (PTH) and PT gland weight. Serum PTH (A)
and parathyroid gland weight (B) in normal and uremic (5/6 nephrecto-compared to those fed a high P diet. Treatment with
mized) rats undergoing one of the following experimental protocols for
either vitamin D metabolite did not increase ionized Ca 7 days: normal  high P (N-HP) diet; uremic (U)  HP diet  vehicle
(U-HP), 1,25D (4 ng/day) (U-HP1,25D), or 19-Nor (30 ng/day)above the levels of normal rats fed the same high P diet.
(U-HP  19-Nor); U  low P diet (U-LP); U  high calcium dietOnly in uremic rats fed a high Ca diet was ionized Ca
(U-HCa). Results represent the mean and SEM from at least 6 rats
higher than normal controls. per group. ANOVA and Bonferroni test were used to compare each
experimental group.
Effects of vitamin D treatment on serum PTH
Figure 1A depicts serum PTH levels in each experimen-
tal condition. Uremic rats fed the high P diet had much the control of serum PTH by either vitamin D treatment
higher serum PTH than normal rats fed the same diet. in the rats fed a high P diet, was similar to that exerted
Both 1,25(OH)2D3 and 19-Nor-1,25(OH)2D2 prevented by P restriction. 1,25(OH)2D3, 19-Nor-1,25(OH)2D2 and
the increase in serum parathyroid hormone induced by P restriction prevented uremia-induced elevations in se-
rum PTH with no increases in ionized Ca levels.high dietary phosphorus. At day 7 after 5/6 nephrectomy,
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Effects of vitamin D treatment on parathyroid
gland growth
There was no contaminating thyroid tissue surround-
ing the parathyroid gland used for weight determinations
as demonstrated in the immunohistochemistry sections.
Figure 1B shows the effects of vitamin D treatment on
PT gland weight. In uremic rats fed high P diet, the
weight of the PT glands was higher than in normal con-
trols fed the same diet. Both 1,25(OH)2D3 and 19-Nor-
1,25(OH)2D2 prevented the enhancement of PT gland
weight observed in uremic rats fed a high P diet. The
growth arrest induced by vitamin D treatment counter-
acting uremia and high dietary P was similar to that
achieved by phosphate restriction in PT glands in which
renal failure was the only growth promoting signal.
To directly measure PT-cell proliferation rates, two
markers of mitotic activity, Ki67 (cell cycle-associated
nuclear antigen) and PCNA (proliferating cell nuclear
antigen), were examined. The number of positive cells
per parathyroid gland area is shown in Figure 2. Higher
levels of both PCNA and Ki67 in PT glands from uremic
rats fed a high phosphorus diet compared to normal
controls. Lower PT-Ki67 and PT-PCNA expression was
observed after seven days in uremic rats fed high P and
treated with either 1,25(OH)2D3 or 19-Nor-1,25(OH)2D2.
At day 7 after the onset of uremia, mitotic activity in
rats fed high P and treated with either vitamin D metabo-
lite was as low as to that observed in P-restricted animals.
Fig. 2. Effects of vitamin D treatment and high dietary Ca on PTThe higher levels of PCNA compared to Ki67 in each
PCNA and Ki67 expression. Parathyroid PCNA (A) and Ki67 expres-experimental group reflect the prolonged half-life of sion (B) in normal and uremic (5/6 nephrectomized) rats undergoing one
PCNA compared to Ki67 after completion of mitosis. of the following experimental protocols for 7 days: normal  high P
(N-HP) diet; uremic (U)  HP diet  vehicle (U-HP), 1,25D (4 ng/day)
(U-HP  1,25D), or 19-Nor (30 ng/day) (U-HP  19-Nor); U  low PEffects of vitamin D treatment on parathyroid
diet (U-LP); U  high calcium diet (U-HCa). Results are expressedp21 expression as positive stained nuclei per area from sections of the whole PT gland
and represent the mean and SEM from at least 6 rats per group. ANOVATo identify the mechanisms mediating the antiprolif-
and Bonferroni test were used to compare each experimental group.erative properties of vitamin D treatment, we first exam-
ined immunohistochemical staining for p21 in PT glands
from rats from each experimental condition. The mixed ment prevented the increases in PT TGF- induced by
cytosolic/nuclear p21 distribution precludes accurate mea- uremia and high dietary P. The efficacy of 1,25(OH)2D3
surement of p21 expression using Image-Pro Plus. Vita- and 19-Nor-1,25(OH)2D2 in preventing increases in TGF-
min D treatment with either 1,25(OH)2D3 or 19-Nor- was similar to that of P restriction (Fig. 4).
1,25(OH)2D2 markedly induced PT-p21 expression in The findings of vitamin D control of TGF- expression
uremic rats fed a high P diet (Fig. 3). The induction of were confirmed in a model of chronic renal failure (Fig. 5).
PT p21 by 1,25(OH)2D3 or 19-Nor-1,25(OH)2D2 (grade Normal and 5/6 nephrectomized rats were fed a high P
) was lower than that achieved with phosphate re- diet. Uremic rats received either vehicle or 100 ng of 19-
striction (grade ), but higher than PT p21 expres- Nor-1,25(OH)2D2 three times weekly for 60 days after
sion in uremic rats fed a high P diet (grade ). the onset of uremia. 19-Nor-1,25(OH)2D2 ameliorated the
increase in PT TGF- induced by chronic renal failure
Effects of vitamin D treatment on parathyroid and high dietary P (Fig. 5).
TGF- expression
Effects of high dietary calcium on serum PTH,Immunohistochemical assessment of PT TGF- levels
parathyroid gland growth, and parathyroid p21was performed using a monoclonal antibody that recog-
and TGF- expressionnizes all TGF- isoforms. As expected, the highest immu-
noreactivity for TGF- was found in the PT glands from High dietary Ca, a well-known promoter of PT growth
arrest in renal failure, prevented both the increase inuremic rats fed a high P diet (Table 2). Vitamin D treat-
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Fig. 3. Effects of vitamin D treatment and high dietary Ca on PT p21 expression. Representative photomicrographs of immunohistochemical
staining of p21 in PT tissue of normal and 5/6 nephrectomized rats undergoing one of the following experimental protocols at day 7 after the
onset of renal failure: normal  high P (N-HP) diet; uremic (U)  HP diet  vehicle (U-HP), 1,25D (4 ng/day) (U-HP  1,25D), or 19-Nor
(30 ng/day) (U-HP  19-Nor); U  low P diet (U-LP); U  high calcium diet (U-HCa). Magnification 400.
Table 2. Semiquantitative analysis of parathyroid (PT) and high phosphorus-induced parathyroid hyperplasia
transforming growth factor- (TGF-) expression
by vitamin D treatment and high dietary calcium.
TGF- IOD/area The molecular mechanisms responsible for uremia in-
N-HP 0.0130.004a duction of PT cell growth are still incompletely under-
U-HP 0.0350.004 stood [3, 14, 15]. Different groups have demonstrated an
U-HP1,25D 0.0090.004a
association between changes in the content of cell cycleU-HP19-Nor 0.0150.001a
U-LP 0.0070.001a regulators and PT hyperplasia in renal failure. Vasef et
U-HCa 0.0160.005a al [16] showed an overexpression of cyclin D1 protein
Values for TGF- represent the mean  SEM from at least 6 rats per group. in human hyperplastic PT glands, while Erickson et al
Abbreviations are in Table 1.
[17] described a reduction of the cyclin-dependent kinasea P  0.01 vs. U-HP, from Bonferroni analysis comparing each experimental
group inhibitor p27Kip1 protein expression in human PT hyper-
plasia compared to normal PT glands.
In experimental models of renal failure in rats, en-
hanced PT cell proliferation rather than hypertrophyserum PTH and PT gland enlargement in early uremia
causes PT gland enlargement [18]. Most PT gland growth(Fig. 1). In fact, lower PT gland weight, PT Ki67 and PT
occurs within four to six days of the onset of renal failurePCNA levels were observed in uremic rats fed a high
[19, 20]. Studies to identify potential mechanisms forCa diet compared to the uremic group fed high P (Fig. 2).
dietary P regulation of PT cell growth in early uremiaHigh dietary Ca enhanced PT p21 content (grade )
demonstrated that high P-induced PT hyperplasia is as-(Fig. 3) and prevented the increases in PT-TGF- expres-
sociated with increased expression of the growth pro-sion (Fig. 4).
moter TGF- [6]. In contrast, PT growth arrest induced
by low dietary P is associated with increased PT expres-
DISCUSSION sion of p21 and occurred in the absence of changes in
These studies demonstrate that the induction of para- serum 1,25(OH)2D3, a direct transcriptional activator of
thyroid p21 and the prevention of increases in TGF- the p21 gene. Dietary P-induced changes in both p21
and TGF- expression are specific for the PT gland [6].are common mediators of the suppression of uremia-
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Fig. 4. Effects of vitamin D treatment and high dietary Ca on PT TGF- expression. Representative photomicrographs of immunohistochemical
staining of TGF- in PT tissue of normal and 5/6 nephrectomized rats undergoing one of the following experimental protocols at day 7 after the
onset of renal failure: normal  high P (N-HP) diet; uremic (U)  HP diet  vehicle (U-HP), 1,25D (4 ng/day) (U-HP  1,25D), or 19-Nor
(30 ng/day) (U-HP  19Nor); U  low P diet (U-LP); U  high calcium diet (U-HCa). Magnification 100.
Fig. 5. Effects of 19-Nor-1,25(OH)2D2 treatment on PT TGF- expression in chronic renal failure. Representative photomicrographs of immunohis-
tochemical staining of TGF- in PT tissue of normal and 5/6 nephrectomized rats undergoing one of the following experimental protocols at day
60 after the onset of renal failure: normal  high P (N-HP) diet; uremic (U)  HP diet  vehicle (U-HP); 19-Nor (100 ng 3/week) (U-HP 
19-Nor). Magnification 100.
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Since vitamin D suppresses PT cell proliferation in In contrast to the antiproliferative properties of en-
hanced PT p21 expression, increases in TGF- contentvitro [7] and in vivo in uremic rats [8], the present studies
specifically addressed the efficacy of vitamin D therapy act as a growth promoter in secondary hyperparathyroid-
ism [23]. Studies in early uremia demonstrating that high(1,25-dihydroxyvitamin D3 and the analog 19-Nor-1,25-
dihydroxyvitamin D2) to counteract the PT hyperplasia dietary P may induce PT cell proliferation by increasing
TGF- expression [6], led us to examine the effects ofinduced by high dietary P in early uremia.
Pilot studies demonstrated that doses of 4 ng of vitamin D treatment on PT TGF- levels. As expected,
the highest immunoreactivity for TGF-was found in the1,25(OH)2D3 and 30 ng of 19-Nor-1,25(OH)2D2 were ef-
fective in controlling PT hyperplasia with no hypercalce- PT glands from uremic rats fed a high P diet. Surprisingly,
both 1,25(OH)2D3 and 19-Nor-1,25(OH)2D2 preventedmic or hyperphosphatemic effects. At these doses, both
vitamin D compounds not only prevented the increase the increases in PT TGF- induced by uremia and high
dietary P. Clearly, in this early uremia model of highin the PTH levels, but also ameliorated the enlargement
of the PT glands induced by uremia and worsened by P-induced PT hyperplasia, there is a direct temporal
correlation between increases in PT TGF- expressionhigh dietary P. The efficacy of 1,25(OH)2D3 and 19-Nor-
1,25(OH)2D2 in controlling both serum PTH and PT and the markers of mitotic activity Ki67 and PCNA. In
contrast, the inhibition of PT gland growth by vitamingland size was similar to that described for P restriction
in the uremic rat model [6], which was utilized in the D therapy associates not only with the induction of PT
p21, but also with the prevention of the increases inpresent protocols as a positive control of PT growth arrest.
Further support for vitamin D control of high P-induced TGF-. Furthermore, 19-Nor-1,25(OH)2D2-control of
PT gland growth in a model of chronic renal failure alsoPT gland growth was provided by immunohistochemical
staining for two markers of mitotic activity: Ki67 and could be partially accounted for the analog preventing
the increases in TGF- expression induced by high di-PCNA. Both 1,25(OH)2D3 and 19-Nor-1,25(OH)2D2 pre-
vented the marked increase in both PT Ki67 and PT PCNA etary P. This is a novel finding suggesting that the control
of PT-TGF- expression by vitamin D treatment couldexpression observed in uremic rats fed the same high P
diet. The higher PCNA staining compared to Ki67 could mediate the antiproliferative properties of 1,25(OH)2D3
and 19-Nor-1,25(OH)2D2 on high P induced-PT hyper-be the result of the longer half-life of PCNA, which allows
immunohistochemical detection of PCNA for a consider- plasia in renal failure. Although a computer analysis of
the rat TGF- promoter indicated no consensus vitaminable time after completion of mitosis [21]. Similar to stud-
ies in several carcinomas [22], our studies revealed that D responsive sequences (VDRE), several mechanisms
could mediate 1,25D transcriptional expression of TGF-.Ki67 is a more accurate marker of PT cell proliferation
in paraffin embedded tissues than PCNA. Similar low Alternative mechanisms for the suppressive effects of
TGF- expression by the 1,25D-vitamin D receptor com-levels of both markers of cell proliferation were present
in uremic rats fed low P or high Ca, two dietary maneu- plex include: (a) a non classical VDRE [24]; (b) a ligand
activated VDR preventing the binding of a transcrip-vers effective in preventing PT gland enlargement.
Liu et al demonstrated that increases in p21 mediate tional activator of the TGF- gene [25, 26] or indirect
effects through induction of intermediary TGF- repres-the antiproliferative effects of 1,25(OH)2D3 in human
monocytes [9]. These authors showed that direct acti- sor proteins [27]. Identification of the mechanisms for
vitamin D inhibition of TGF- expression demands fur-vation of p21-gene transcription was sufficient for 1,25
(OH)2D3 to suppress growth in the human myelomono- ther investigation.
Studies in psoriasis, a hyperproliferative disorder ofcytic cell line U937 [9]. The present studies confirm that
vitamin D treatment also induces the expression of p21 the skin, provide some indirect evidence of the impact
of down-regulation of TGF- expression by vitamin Dprotein in rat PT glands. Further support for these find-
ings came from studies in patients with secondary hyper- treatment in growth arrest. TGF- regulates the growth
of normal and neoplastic cells in various tissues. TGF-parathyroidsm (abstract; Tokumoto et al, J Am Soc
Nephrol 11: 584A, 2000). A strong correlation was found mRNA and protein are expressed in human keratino-
cytes [28]. TGF- expression in psoriatic epidermis isbetween the more aggressive nodular form of PT growth
and reduced p21 expression. In these patients, the lower higher than in normal skin [29]. In view of the efficacy
of 1,25(OH)2D3 and its less calcemic analogs in the treat-PT p21 content, the lower the expression of the vitamin
D receptor. This finding suggests that 1,25(OH)2D3 ment of psoriasis [30, 31], as well as our findings in uremic
PT growth, it is possible that 1,25(OH)2D3 and vitamininduction of PT p21 also involves enhancement of p21
gene transcription by the 1,25(OH)2D3-vitamin D re- D analogs arrest psoriatic keratinocyte proliferation by
preventing increases in TGF- expression. In fact, pre-ceptor complex. Clearly, 1,25(OH)2D3 and 19-Nor-1,25
(OH)2D2 induction of PT p21 expression could partially liminary studies in our laboratory using the human kera-
tinocyte cell line A431, which mimic psoriatic keratino-account for the antiproliferative effects of both sterols
on high P-induced PT hyperplasia. cytes in overexpressing TGF-, demonstrate that the
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